Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 2/3 1

Status

Recruiting 5Unknown 3Completed 3Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 96Myelodysplastic Syndromes 20Leukemia, Myelomonocytic, Chronic 10Recurrence 8Leukemia 8Neoplasm, Residual 6Hematologic Neoplasms 6Myeloproliferative Disorders 5Lymphoma, T-Cell, Peripheral 5Leukemia, Biphenotypic, Acute 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic-Myeloproliferative Diseases 3Leukemia, Monocytic, Acute 3Anemia, Refractory, with Excess of Blasts 3Neoplasm Metastasis 2Myeloid Malignancy 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2GATA2 Deficiency 2Breast Neoplasms 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Myeloid 1Pyloric Stenosis, Hypertrophic 1Primary Myelofibrosis 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9Cyclophosphamide 9Prednisone 8Doxorubicin 7Vincristine 6Azacitidine 5pembrolizumab 3fludarabine 3belinostat 3Lenalidomide 3Brentuximab Vedotin 310-propargyl-10-deazaaminopterin 3ruxolitinib 2duvelisib 2Gemcitabine 2Dexamethasone 2Biopsy 2Bendamustine Hydrochloride 2venetoclax 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1pomalidomide 1ixazomib 1ivarmacitinib 1daratumumab 1cemiplimab 1calaspargase pegol 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, T-Cell, Peripheral × Azacitidine × Clear all
NCT05182957 2026-05-01

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

The First Affiliated Hospital of Soochow University

Phase 2 Recruiting
31 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT07389616 2026-02-05

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2/3 Recruiting
40 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

CellCentric Ltd.

Phase 1/2 Recruiting
250 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT05958719 2024-12-30

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
37 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06176027 2024-10-29

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas

Navy General Hospital, Beijing

Phase 1/2 Recruiting
52 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡